Abstract
Ipratropium (40 micrograms) and theophylline (oxtriphylline 400 mg) were administered to 24 asthmatics in a randomized double-blind placebo controlled trial. The combination of these agents produced additive bronchodilation for up to two hours, with a 23 percent maximal increase in FEV1. This regimen promises to be safe, effective therapy for patients with asthma.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Asthma / diagnosis
-
Asthma / drug therapy*
-
Asthma / physiopathology
-
Atropine Derivatives / therapeutic use*
-
Bronchodilator Agents / therapeutic use
-
Drug Therapy, Combination
-
Female
-
Forced Expiratory Volume
-
Humans
-
Ipratropium / therapeutic use*
-
Male
-
Maximal Midexpiratory Flow Rate
-
Middle Aged
-
Theophylline / therapeutic use*
Substances
-
Atropine Derivatives
-
Bronchodilator Agents
-
Theophylline
-
Ipratropium